The proto-oncogene MDM2 is a nuclear-localized E3 ubiquitin ligase, which promotes tumor formation by targeting tumor suppressor proteins, such as p53, for proteasomal degradation. In this study, the anti-infective drug nitroxoline (NXQ) was screened out to effectively inhibit cell survival of small-cell lung cancer (SCLC) cells, and induce SCLC cell apoptosis by suppressing antiapoptotic proteins (such as Bcl-2 and MCL1) and upregulating proapoptotic protein Bim. In the mechanistic study, NXQ was found to downregulate MDM2 expression by inducing its proteasomal degradation, and thus upregulated p53 expression, which was a substrate protein of MDM2. Moreover, over- p53, a well-known tumor suppressor, is closely associated with diverse cellular signals involved in cell cycle, cell apoptosis, cell metabolism, and so on. 5 Tight regulation of p53 is essential for maintaining normal cell growth, and E3 ubiquitin ligase MDM2-mediated p53 degradation is generally considered as the major mechanism for p53 regulation. 6 Recently, the studies showed that the C-terminus of p53 contained the oligomerization domain, which was required for the MDM2-dependent proteasomal degradation of p53. 7 Therefore, targeting the MDM2/p53 axis has been an actively sought-after strategy for novel antitumor drug discovery.
1 Although small-cell lung cancer (SCLC) accounts for only 15% to 20% of all lung cancer cases, 60% of patients have extrathoracic metastases at the time of diagnosis, and few of them can survive more than 1 year, which gives a major challenge for the health care system. 2, 3 Despite significant progress has been done, there are still a few new small molecular drugs and biologics that have benefited patients with SCLC markedly. 4 Thus, development of novel drugs for SCLC treatment is urgent.
p53, a well-known tumor suppressor, is closely associated with diverse cellular signals involved in cell cycle, cell apoptosis, cell metabolism, and so on. 5 Tight regulation of p53 is essential for maintaining normal cell growth, and E3 ubiquitin ligase MDM2-mediated p53 degradation is generally considered as the major mechanism for p53 regulation. 6 Recently, the studies showed that the C-terminus of p53 contained the oligomerization domain, which was required for the MDM2-dependent proteasomal degradation of p53. 7 Therefore, targeting the MDM2/p53 axis has been an actively sought-after strategy for novel antitumor drug discovery.
In this study, the anti-infective drug nitroxoline (NXQ) was screened out to display significant anti-SCLC activity through suppressing MDM2 expression. These results indicated that NXQ could be potentially repurposed as a chemotherapeutic drug for the treatment of SCLC in the future. 
| Immunoblotting
The whole cell lysates were prepared for immunoblotting as described previously. 9 The primary antibodies against PARP, Bcl-2, MCL1, Bim, MDM2, and p53 were purchased from Cell Signaling Technology 
| Quantitative real-time polymerase chain reaction
The quantitative real-time polymerase chain reaction (qRT-PCR) was performed as described previously. 8 
| Plasmids construction and gene transfection
The human MDM2 gene was generated and cloned into pcDNA3.1
vector with a Myc tag as previously described. 10 Plasmids were transiently transfected into H446 or H1882 cells by Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instruction.
| Statistical analysis
The student's t test was used for comparisons of two groups in the studies, and all statistical tests were two-sided. A P value <0.05 was considered statistically significant. Figure 1A and Table 1 
| NXQ downregulates MDM2 expression in SCLC
Proto-oncogene MDM2 promotes tumorigenesis by targeting tumor suppressor proteins, such as p53, for proteasomal degradation. 11 In this study, a panel of SCLC cell lines was treated with 20 μM NXQ for 24 hours, followed by immunoblotting assay ( Figure 3A ). And the results showed that NXQ significantly downregulated the protein level of MDM2, along with p53 upregulation F I G U R E 2 Nitroxoline (NXQ) induces cell apoptosis in small-cell lung cancer (SCLC) cells. A, H446 cells were treated with increasing concentrations of NXQ for indicated time, followed by Cell Counting Kit-8 (CCK-8) staining. B, H1882 cells were treated with increasing concentrations of NXQ for indicated time, followed by CCK-8 staining. C, H446, H1882, and H1417 cells were treated with increasing concentrations of NXQ for 24 hours, followed by immunoblotting against PARP. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a loading control. D, H446, H1882, and H1417 cells were treated with increasing concentrations of NXQ for 24 hours, followed by immunoblotting against Bcl-2, MCL1, Bim, and GAPDH ( Figure 3A) . To further confirm this result, H446 and H1882 cells were treated with increasing concentrations of NXQ for 24 hours, and the immunoblotting revealed that NXQ downregulated MDM2 expression in a concentration-dependent manner, along with increasing p53 expression ( Figure 3B ). In addition, the effects of NXQ on downregulating MDM2 and upregulating p53 were also in a time-dependent manner ( Figure 3C ).
| Overexpression of MDM2 decreases the cytotoxicity of NXQ on SCLC cells
To further assess the specificity of NXQ on MDM2 inhibition, the overexpressed plasmid of MDM2 was generated and transfected into H446or H1882 cells individually. As shown in Figure 4A ,C, overexpression of MDM2 markedly decreased NXQ-induced cell survival of both H446 and H1882 cells. Moreover, the immunoblotting assays showed F I G U R E 3 Nitroxoline (NXQ) downregulates MDM2 expression in smallcell lung cancer (SCLC) cells. A, H446, H1688, and H1882 cells were treated with 0 or 20 μM NXQ for 24 hours, followed by immunoblotting against MDM2 and p53. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a loading control. B, H446 and H1882 cells were treated with increasing concentrations of NXQ for 24 hours, and then cells were prepared for immunoblotting against MDM2, p53, and GAPDH. C, H446 and H1882 cells were treated with 10 μM NXQ for indicated time, and then cells were prepared for immunoblotting against MDM2 and p53. GAPDH was used as a loading control 
| NXQ induces MDM2 degradation via the proteasomal pathway
To further evaluate how NXQ downregulated MDM2 expression, the total mRNAs from NXQ-treated cells were extracted. As shown in Figure 5A ,B, the qRT-PCR showed that NXQ did not affect the mRNA levels of MDM2 in H446 and H1882 cells, which indicated that NXQ regulated the stability of MDM2 protein.
It was known that the proteasomal and lysosomal pathways were the two main ways for protein degradation. 12 Then, the proteasome inhibitor MG132 or lysosome inhibitor CHQ alone or with NXQ were incubated with H446 cells for 12 hours, and the immunoblotting showed that MG132 but not CHQ prevented NXQ-induced MDM2 degradation, suggesting that NXQ induced MDM2 degradation via the proteasome ( Figure 5C ,D).
| DISCUSSION
Nitroxoline, an FDA-approved antibiotic, was identified to display antitumor activity, which was considered to be repurposed for tumor therapy.
13
A recent study reported that NXQ was screened out to show antimyeloma activity both in vitro and in vivo by targeting the TRIM25/ p53 axis. 14 In cholangiocarcinoma cells, NXQ also exhibited anticancer activity by inducing FoxM1 inhibition. 15 NXQ was also considered as a potent and selective inhibitor of cathepsin B, hence reducing glioma tumor progression in vitro and in vivo, and a number of derivatives of NXQ were developed by using structure-based chemical synthesis in order to further improve its antitumor properties. 16, 17 In this study, NXQ was found to suppress SCLC cell survival and induce SCLC cell apoptosis (Figures 1 and 2) . These above indicated that it was conceivable that the widely used antibacterial agent NXQ might be tried for SCLC treatment in clinic.
MDM2 was considered as an oncoprotein and elevated MDM2 was frequently occurred in human lung tumor tissues. 18 In the tumor cells without p53 mutation, p53, the tumor suppressor, was often inactivated by some mechanisms, such as overexpression of its negative regulator MDM2. 19 It had been proven that MDM2/p53 axis was widely regarded as an attractive therapeutic target in a broad range of tumors, including SCLC. 20 In this study, NXQ was found to inhibit the E3 ligase MDM2 expression by inducing its proteasomal degradation, and thus upregulated the protein level of p53, which was a substrate of MDM2 (Figures 3 and 5) . Interestingly, Shim et al.
also observed similar phenomena with another interpretation that NXQ induced the premature senescence of endothelial cells by increasing the level of acetylated p53 through inhibition of both MetAP2 and SIRT1. 21 Noteworthily, a number of MDM2 inhibitors F I G U R E 5 Nitroxoline (NXQ) induces MDM2 degradation via the proteasomal pathway. A, H446 cells were treated with NXQ at indicated concentrations for 24 hours, followed by quantitative real-time polymerase chain reaction (qRT-PCR) against MDM2 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). B, H1882 cells were treated with NXQ at indicated concentrations for 24 hours, followed by qRT-PCR against MDM2 and GAPDH. C, H446 cells were treated with NXQ alone or with MG132 or chloroquine (CHQ) for 12 hours, followed by immunoblotting against MDM2. GAPDH was used as an internal control. D, Statistical analysis for MDM2/GAPDH of (C). Abbreviation: n.s., nonsense has been also found as potential antitumor agents. For example, MDM2 inhibitor SAR405838 was a potent therapeutic drug for neuroblastoma by inducing p53-mediated apoptosis. 22 SAR405838 restored p53 function by blocking the interaction between MDM2 and p53. 22 Nutlin-3 was a potent and selective MDM2 antagonist, and it could stabilize p73 protein in p53-deficient cells. 23 
| CONCLUSION
Nitroxoline is thus shown to be a potent MDM2 inhibitor by inducing its proteasomal degradation, and displays significant antitumor activity in SCLC cells. The effect of NXQ in vivo might be also worth for further investigation in the future.
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